Co-silencing of both SP1 and SP3 or treatment with Mithramycin A (SP transcription inhibitor) repressed MALAT1 expression in HCC cells [155], which suggests another potential pathway via which SP transcription factors may contribute to HCC. This evidence concerns the gene TFF2 and hepatocellular carcinoma.